Register for our free email digests:
Swedish Orphan Biovitrum AB
www.sobi.com
Latest From Swedish Orphan Biovitrum AB
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
Bavarian Nordic Transformed By GSK Vaccines Buy
Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Sobi
- Biovitrum AB
- Swedish Orphan Biovitrum
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Sweden
-
Sweden
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Swedish Orphan Biovitrum AB
- Senior Management
-
Guido Oelkers, PhD, CEO
Henrik Stenqvist, CFO
Milan Zdravkovic, MD, PhD, Head, R&D & CMO - Contact Info
-
Swedish Orphan Biovitrum AB
Phone: (46) 8 697 20 00
Tomtebodavägen 23A
Stockholm, SE-112 76
Sweden
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice